FDA approves Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for ...

The FDA has approved Roche's Tecentriq in combination with fluoropyrimidine and oxaliplatin as the first immunotherapy-based adjuvant treatment for stage III deficient DNA mismatch repair (dMMR) colon cancer. This approval follows the landmark phase III ATOMIC trial, which demonstrated a 50% reduction in the risk of disease recurrence or death compared to chemotherapy alone.

This Wire brief sits within Fusion42's coverage of Biotech.